104 related articles for article (PubMed ID: 16733218)
21. Multiple primary lung adenocarcinomas pre-operatively diagnosed by discordant epidermal growth factor receptor mutations.
Katayama Y; Kawai S; Miyagawa-Hayashino A; Takemura Y
Respirol Case Rep; 2019 Aug; 7(6):e00434. PubMed ID: 31139414
[TBL] [Abstract][Full Text] [Related]
22. Triple-Negative Metaplastic Breast Carcinoma: Association of Epidermal Growth Factor Receptor Expression With Prognostic Parameters and Clinical Outcome.
Munawar S; Haider R; Ali SM; Yaqeen SR; Islam S; Asghar IA; Afzal A; Zia S; Irfan M; Hashmi AA
Cureus; 2021 May; 13(5):e15006. PubMed ID: 34150374
[TBL] [Abstract][Full Text] [Related]
23. Randomized phase II study of fulvestrant and erlotinib compared with erlotinib alone in patients with advanced or metastatic non-small cell lung cancer.
Garon EB; Siegfried JM; Stabile LP; Young PA; Marquez-Garban DC; Park DJ; Patel R; Hu EH; Sadeghi S; Parikh RJ; Reckamp KL; Adams B; Elashoff RM; Elashoff D; Grogan T; Wang HJ; Dacic S; Brennan M; Valdes Y; Davenport S; Dubinett SM; Press MF; Slamon DJ; Pietras RJ
Lung Cancer; 2018 Sep; 123():91-98. PubMed ID: 30089602
[TBL] [Abstract][Full Text] [Related]
24. Role of HER2 mutations in refractory metastatic breast cancers: targeted sequencing results in patients with refractory breast cancer.
Park YH; Shin HT; Jung HH; Choi YL; Ahn T; Park K; Lee A; Do IG; Kim JY; Ahn JS; Park WY; Im YH
Oncotarget; 2015 Oct; 6(31):32027-38. PubMed ID: 26397225
[TBL] [Abstract][Full Text] [Related]
25. Investigating Molecular Mechanisms of Activation and Mutation of the HER2 Receptor Tyrosine Kinase through Computational Modeling and Simulation.
Telesco SE; Shih A; Liu Y; Radhakrishnan R
Cancer Res J; 2011; 4(4):1-35. PubMed ID: 25346782
[TBL] [Abstract][Full Text] [Related]
26. Molecular modeling of ErbB4/HER4 kinase in the context of the HER4 signaling network helps rationalize the effects of clinically identified HER4 somatic mutations on the cell phenotype.
Telesco SE; Vadigepalli R; Radhakrishnan R
Biotechnol J; 2013 Dec; 8(12):1452-64. PubMed ID: 24318637
[TBL] [Abstract][Full Text] [Related]
27. Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology.
Lindeman NI; Cagle PT; Beasley MB; Chitale DA; Dacic S; Giaccone G; Jenkins RB; Kwiatkowski DJ; Saldivar JS; Squire J; Thunnissen E; Ladanyi M
J Thorac Oncol; 2013 Jul; 8(7):823-59. PubMed ID: 23552377
[TBL] [Abstract][Full Text] [Related]
28. Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology.
Lindeman NI; Cagle PT; Beasley MB; Chitale DA; Dacic S; Giaccone G; Jenkins RB; Kwiatkowski DJ; Saldivar JS; Squire J; Thunnissen E; Ladanyi M
Arch Pathol Lab Med; 2013 Jun; 137(6):828-60. PubMed ID: 23551194
[TBL] [Abstract][Full Text] [Related]
29. A comparison of EGFR mutation testing methods in lung carcinoma: direct sequencing, real-time PCR and immunohistochemistry.
Angulo B; Conde E; Suárez-Gauthier A; Plaza C; Martínez R; Redondo P; Izquierdo E; Rubio-Viqueira B; Paz-Ares L; Hidalgo M; López-Ríos F
PLoS One; 2012; 7(8):e43842. PubMed ID: 22952784
[TBL] [Abstract][Full Text] [Related]
30. Intrinsic and acquired resistance to HER2-targeted therapies in HER2 gene-amplified breast cancer: mechanisms and clinical implications.
Rexer BN; Arteaga CL
Crit Rev Oncog; 2012; 17(1):1-16. PubMed ID: 22471661
[TBL] [Abstract][Full Text] [Related]
31. Is high resolution melting analysis (HRMA) accurate for detection of human disease-associated mutations? A meta analysis.
Li BS; Wang XY; Ma FL; Jiang B; Song XX; Xu AG
PLoS One; 2011; 6(12):e28078. PubMed ID: 22194806
[TBL] [Abstract][Full Text] [Related]
32. Receptor-tyrosine-kinase-targeted therapies for head and neck cancer.
Elferink LA; Resto VA
J Signal Transduct; 2011; 2011():982879. PubMed ID: 21776391
[TBL] [Abstract][Full Text] [Related]
33. Mutations in the epidermal growth factor receptor (EGFR) gene in triple negative breast cancer: possible implications for targeted therapy.
Teng YH; Tan WJ; Thike AA; Cheok PY; Tse GM; Wong NS; Yip GW; Bay BH; Tan PH
Breast Cancer Res; 2011 Apr; 13(2):R35. PubMed ID: 21457545
[TBL] [Abstract][Full Text] [Related]
34. Somatic mutation of epidermal growth factor receptor in a small subset of cutaneous squamous cell carcinoma.
Ridd K; Bastian BC
J Invest Dermatol; 2010 Mar; 130(3):901-3. PubMed ID: 19812598
[No Abstract] [Full Text] [Related]
35. Atomistic insights into regulatory mechanisms of the HER2 tyrosine kinase domain: a molecular dynamics study.
Telesco SE; Radhakrishnan R
Biophys J; 2009 Mar; 96(6):2321-34. PubMed ID: 19289058
[TBL] [Abstract][Full Text] [Related]
36. Evaluation of high-resolution melting analysis as a diagnostic tool to detect the BRAF V600E mutation in colorectal tumors.
Pichler M; Balic M; Stadelmeyer E; Ausch C; Wild M; Guelly C; Bauernhofer T; Samonigg H; Hoefler G; Dandachi N
J Mol Diagn; 2009 Mar; 11(2):140-7. PubMed ID: 19213871
[TBL] [Abstract][Full Text] [Related]
37. The use of EGFR exon 19 and 21 unlabeled DNA probes to screen for activating mutations in non-small cell lung cancer.
Willmore-Payne C; Holden JA; Wittwer CT; Layfield LJ
J Biomol Tech; 2008 Jul; 19(3):217-24. PubMed ID: 19137110
[TBL] [Abstract][Full Text] [Related]
38. Overcoming resistance to tyrosine kinase inhibitors: lessons learned from cancer cells treated with EGFR antagonists.
Rexer BN; Engelman JA; Arteaga CL
Cell Cycle; 2009 Jan; 8(1):18-22. PubMed ID: 19106609
[TBL] [Abstract][Full Text] [Related]
39. High resolution melting analysis for rapid and sensitive EGFR and KRAS mutation detection in formalin fixed paraffin embedded biopsies.
Do H; Krypuy M; Mitchell PL; Fox SB; Dobrovic A
BMC Cancer; 2008 May; 8():142. PubMed ID: 18495026
[TBL] [Abstract][Full Text] [Related]
40. High resolution melting for mutation scanning of TP53 exons 5-8.
Krypuy M; Ahmed AA; Etemadmoghadam D; Hyland SJ; ; DeFazio A; Fox SB; Brenton JD; Bowtell DD; Dobrovic A
BMC Cancer; 2007 Aug; 7():168. PubMed ID: 17764544
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
